Progress in the understanding and treatment of chronic anal fissure

K McCallion, K R Gardiner

Abstract

Background—Chronic anal fissure is a common and painful condition associated with internal anal sphincter hypertonia. Reduction of this hypertonia improves the local blood supply, encouraging fissure healing. Surgical sphincterotomy is very successful at healing these fissures but requires an operation with associated morbidity. Temporary reduction in sphincter tone can be achieved on an outpatient basis by applying a topical nitric oxide donor (for example, glyceryl trinitrate) or injecting botulinum toxin into the anal sphincter.

Methods—A Medline database was used to perform a literature search for articles relating to the non-surgical treatment of chronic anal fissure.

Results—Review of the literature shows botulinum toxin injection to be more effective at healing chronic anal fissures than topical glyceryl trinitrate. Topical isosorbide dinitrate has not been directly compared with either of these two agents but has a healing rate approaching that of botulinum toxin injection. The main side effect of botulinum toxin injection is temporary faecal incontinence in approximately 2% of cases, whereas topical nitrates cause headaches in 20%–100% of cases. No long term side effects were identified with any of the medical treatments.

Conclusion—Chemical sphincterotomy is an effective treatment for chronic anal fissure and has the advantages over surgical treatment of avoiding long term complications (notably incontinence) and not requiring hospitalisation.

Keywords: chronic anal fissure; sphincterotomy; glyceryl trinitrate; botulinum toxin

Background

An anal fissure is a split in the mucosa extending from the anal verge towards the dentate line. It was first recognised as a disease in 1934 and currently affects 10% of patients attending proctology clinics. Fissures usually present with pain and small amounts of bright red rectal bleeding. Contrary to traditional teaching, a precipitating history of constipation is found only in a small percentage of patients (approximately 20%).

Acute fissures usually heal with conservative management. Fissures lasting greater than two months with features of chronicity (Sentinel skin tag, hypertrophied anal papilla, exposure of the underlying internal anal sphincter or anal cicatrisation) are unlikely to heal with conservative management. Fissures due to an underlying disease (for example, perianal Crohn's disease where fissures are often multiple and situated laterally) are also unlikely to resolve with conservative management.

Aetiology

The internal anal sphincter hypertonia seen in patients with an anal fissure has long been thought to be a secondary phenomenon, occurring after local trauma to the mucosa by, for example, the passage of hard faeces. In this scenario, subsequent sphincter spasm then leads to further constipation and so a vicious cycle is created. Traditional treatment (anal dilatation and internal sphincterotomy) aims to break this cycle by disrupting the internal anal sphincter.

Recent research has shown the blood flow to the posterior midline of the anus to be potentially deficient, being supplied by end arteries (mean arteriolar blood pressure 85 mm Hg) which pass through the internal anal sphincter before reaching the posterior commissure. As the maximum resting anal pressure (MRAP) is usually greater than 90 mm Hg in patients with fissures, such hypertonia will compress these end arteries and cause ischaemia of the posterior commissure. Such a reduction in the posterior anodermal blood flow has been confirmed using laser Doppler flowmetry. Further evidence that the hypertonia is not secondary to pain arises from the demonstration that it is not relieved by the use of topical anaesthetics.

This evidence supports the hypothesis that anal fissures are caused by internal anal sphincter hypertonia producing ischaemia of the posterior commissure of the anus. This explains the presence of sphincter spasm, severe pain (ischaemic in nature), predilection for the posterior midline, and poor healing. It
Table 1 Clinical trials of chemical sphincterotomy

<table>
<thead>
<tr>
<th>Reference</th>
<th>Treatment</th>
<th>Trial design</th>
<th>No of patients</th>
<th>Healing rate</th>
<th>Incontinence rate for flatus (F) or stool (S)</th>
<th>Headache rate</th>
<th>Relapse rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lund and Scholefield</td>
<td>0.2% GTN v white soft paraffin</td>
<td>PRCT</td>
<td>80</td>
<td>68% at 8 w</td>
<td>0%</td>
<td>58%*</td>
<td>8% at 4 m‡</td>
</tr>
<tr>
<td>Carapeti et al</td>
<td>0.2-0.6% GTN v yellow paraffin</td>
<td>PRCT</td>
<td>70</td>
<td>67.2% at 8 w of treatment</td>
<td>F: 13%</td>
<td>72%</td>
<td>29% at 6-14 m‡</td>
</tr>
<tr>
<td>Bacher et al</td>
<td>0.2% GTN v lignocaine gel</td>
<td>PRCT</td>
<td>13</td>
<td>62% at 4 w</td>
<td>0%</td>
<td>20%, mild</td>
<td>0% at 4 w</td>
</tr>
<tr>
<td>Lyssy et al</td>
<td>1.25–2.5 mg ISDN spray</td>
<td>Uncontrolled</td>
<td>41</td>
<td>83% at 4 w</td>
<td>—</td>
<td>19.5%, 18% at 3–17 m‡</td>
<td></td>
</tr>
<tr>
<td>Schouten et al</td>
<td>1% ISDN</td>
<td>Uncontrolled</td>
<td>34</td>
<td>88% at 12 w</td>
<td>0%</td>
<td>100%, mild</td>
<td>7% at 10 w</td>
</tr>
<tr>
<td>Maria et al</td>
<td>BoTx 20U v saline</td>
<td>PRCT</td>
<td>30</td>
<td>73% at 8 w, 100% with 2nd dose</td>
<td>F: 4%</td>
<td>—</td>
<td>0% at 16 m</td>
</tr>
<tr>
<td>Jost</td>
<td>BoTx 5 IU</td>
<td>Uncontrolled</td>
<td>100</td>
<td>79% at 6 m</td>
<td>F: 7%, S: 2%</td>
<td>—</td>
<td>8% at 6 m</td>
</tr>
<tr>
<td>Mason et al</td>
<td>BoTx 0.125–1 mg</td>
<td>Uncontrolled</td>
<td>15</td>
<td>60% at 6 m</td>
<td>0%</td>
<td>0% at 6 m</td>
<td></td>
</tr>
<tr>
<td>Cook et al</td>
<td>Nifedipine 20 mg orally</td>
<td>Uncontrolled</td>
<td>15</td>
<td>60% at 8 w</td>
<td>0%</td>
<td>27%, mild (67%)</td>
<td>7% at 1 m‡</td>
</tr>
<tr>
<td>Brisinda et al</td>
<td>BoTx 20U v 0.2% GTN twice daily</td>
<td>PRT</td>
<td>25</td>
<td>96% at 2 w **</td>
<td>0%</td>
<td>0%*</td>
<td>0% at 16 m</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60% at 2 w ***</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*One patient discontinued treatment because of severe headaches.
†All successfully retreated.
‡44% successfully retreated with GTN.
§No rescue treatment given.
¶Successfully retreated with topical GTN.
**All patients successfully treated by crossing over to the alternative treatment.

GTN = glyceryl trinitrate, ISDN = isosorbide dinitrate, BoTx = botulinum toxin, PRCT = prospective randomised control trial, PRT = prospective randomised trial, m = months, w = weeks.

also explains how surgery to disrupt the internal anal sphincter and improve anodermal blood flow allows the fissure to heal.

Surgical sphincterotomy

Although acute anal fissures usually respond to conservative management, lateral internal sphincterotomy has been the treatment of choice for chronic anal fissures.7 Sphincterotomy was first described in 1835 and can be carried out using an open or a subcutaneous technique and under local or general anaesthesia. Two large studies have demonstrated a 2.3%–3% failure rate at five years.8 10 The median time to fissure healing was 5.6 weeks, with incontinence for flatus occurring in 3%–36%, soiling in 4.4%–21%, and faecal incontinence in 0.4%–4.9%. The extent of sphincterotomy may influence the subsequent outcome (in terms of healing and incontinence) and it would appear reasonable to divide the sphincter for the length of the fissure.11 12 It has been suggested that open sphincterotomies are longer than closed ones,12 explaining why they have been shown to have a higher risk of incontinence than the closed technique.13 Various studies have shown lateral internal sphincterotomy to be superior to anal dilatation and posterior internal sphincterotomy.14 15 Posterior internal sphincterotomy results in a keyhole deformity of the anal canal and a wound which is slow to heal, presumably because of the inadequate blood supply.

Anal dilatation

Anal dilatation was first described in 183816 and was popularised by Lord in the treatment of haemorrhoids.17 Lord’s original eight finger dilatation was abandoned in favour of a more gentle four finger stretch for four minutes1 and more recently a standardised dilatation procedure using a Parks’ retractor opened to 4.8 cm or with a 40 mm rectosigmoid balloon has been advocated in the treatment of chronic anal fissures.18 Although anal dilatation results in successful healing of anal fissures comparable to lateral internal sphincterotomy, there is no way to reliably standardise the procedure and both the internal and external sphincters can be disrupted or fragmented in an irregular manner.20 21 Nielsen et al have used postoperative endoanal ultrasound to show that sphincter damage occurs in 65% of patients undergoing anal dilatation with minor anal incontinence occurring in 12.5% of cases.22 Retrospective22 and prospective14 22 trials have shown that anal dilatation has a higher risk of incontinence than that of lateral internal sphincterotomy. Saad and Omer demonstrated anal incontinence in 4.8% of patients undergoing lateral internal sphincterotomy (1/21) but in 24.3% (9/37) of patients after anal dilatation, although some authors still support a policy of gentle anal dilatation as the treatment of choice in chronic anal fissure.23

Chemical sphincterotomy—nitric oxide donor

The mediator of the non-adrenergic non-cholinergic pathway stimulating relaxation of the internal sphincter has been shown to be nitric oxide.24 Application of topical nitric oxide donors has been shown to reduce anal pressure.24 Such observations have generated an interest in the use of nitric oxide donors as a form of chemical sphincterotomy (table 1).

A prospective, randomised, double blind, placebo controlled trial in 80 recruited patients with chronic anal fissures revealed a 68% (26/38 cases) healing rate at eight weeks when 0.2% glyceryl trinitrate ointment was applied twice daily compared with an 8% (3/39 cases) healing rate for placebo.25 Healing correlated with a reduction in pain, reduced MRAP, and an improvement in anodermal blood flow. There was an 8% relapse rate at four months but these three patients were successfully retreated with glyceryl trinitrate ointment and no further relapse had been recorded four months later. Long term results are awaited. The median time to healing was six weeks, with 58% of patients developing headaches and one
patient (2.6%) required surgery after stopping the treatment for this reason. There were no cases of incontinence. The MRAP has been shown to return to pre-treatment levels once the glyceryl trinitrate has been stopped.34

A more recent prospective, randomised, double blind, placebo controlled trial in 70 patients with chronic anal fissures revealed a 65% (15/23 cases) healing rate at two weeks after an eight week course of 0.2% glyceryl trinitrate ointment applied three times a day compared to 32% (7/22 cases) for placebo.35 The median time to healing was eight weeks. Increasing the strength of glyceryl trinitrate ointment to a maximum of 0.6% did not improve healing efficacy (16/23, 70%). Glyceryl trinitrate treatment caused a significantly bigger reduction in MRAP compared with the placebo group but this was not associated with an improvement in anodermal blood flow. During a median follow up of nine months, symptomatic recurrence rates were 43% for the placebo group (3/7), 33% for the 0.2% glyceryl trinitrate group (5/15), and 25% for the higher dose glyceryl trinitrate group (4/16). Forty per cent of these recurrences were successfully treated with a second course of glyceryl trinitrate. Seventy two per cent of patients receiving glyceryl trinitrate developed headaches, with no difference between the low and high dose groups (15/23 v 18/23 respectively). Temporary loss of flatus control was observed in 6/46 patients during glyceryl trinitrate treatment, with no case of faecal incontinence. This study therefore reports higher rates of side effects (headache and temporary loss of flatus control) and higher recurrence rates than that of Lund et al above.34 Also, although glyceryl trinitrate application caused fissure healing and a reduction in MRAP, there was no measurable increase in anodermal blood flow observed after eight weeks in this study. This is contrary to the hypothesis that glyceryl trinitrate heals fissures by improving blood flow to an essentially ischaemic ulcer and in contrast to other studies which have documented improved anodermal blood flow with the use of topical nitric oxide donors.35 36 Carapeti et al assumed that their unexpected finding of no increase in anodermal blood flow was due to homeostatic mechanisms responsible for regulation of cutaneous blood flow compensating for the vasodilatory effect of glyceryl trinitrate.35

A smaller prospective, randomised, controlled trial using 0.2% glyceryl trinitrate ointment applied three times a day produced a one month healing rate of 62.5% (five of eight patients with chronic anal fissure) compared with 20% (one of five patients) when 2% lignocaine was used.37 Of interest, the MRAP was not significantly lowered during the one month study period in four of the five patients successfully treated by glyceryl trinitrate. Of a total of 20 patients treated with glyceryl trinitrate (12 acute and eight chronic fissures), 20% suffered mild headache and there was no report of incontinence. The one month healing rate for acute anal fissures was also significantly improved (91.6% with glyceryl trinitrate v 50% with lignocaine).

It has been suggested that tachyphylaxis may occur when glyceryl trinitrate is used to treat anal fissure,39 just as it occurs in cardiovascular disease. Higher doses may overcome this problem as there is some evidence that the internal anal sphincter demonstrates a dose related response to the application of glyceryl trinitrate.39

A potential problem with using glyceryl trinitrate ointment outside of a trial setting may be poor compliance. A retrospective mail audit of 27 patients who were prescribed glyceryl trinitrate ointment 0.2% twice daily reported a compliance rate of 67% with a healing rate of only 56% after three to 10 weeks of treatment.40

An uncontrolled prospective observational study looked at the use of isosorbide dinitrate spray in the treatment of anal fissures.41 In 41 patients studied, symptoms had been present for two to 120 months with classical signs of chronicity present in only 61% of cases. All the patients had failed to heal after three weeks of conservative management. In this group of patients, isosorbide dinitrate 1.25 or 2.5 mg (one or two sprays) applied three times a day for four weeks produced healing in 83% (34/41) of patients at four months. A second four week course of isosorbide dinitrate produced healing in one more patient. There was an 18% relapse rate (6/34) after a mean follow up of 11 months, all of which were successfully retreated with a further four week course of isosorbide dinitrate. Patients with an anal fissure of long duration were more likely to relapse than those of shorter duration, showing the importance of such factors when comparing different studies. During the follow up, a further 12% (4/34) of patients developed mild symptoms which were successfully treated with the use of isosorbide dinitrate for not more than four days. There was a significantly greater reduction in MRAP in those patients where the anal fissure was healed compared to those where treatment failed. Headaches occurred in 19.5% of patients, with one patient discontinuing treatment due to severe headaches. Higher doses (3.75 mg or 5 mg) of isosorbide dinitrate resulted in headaches in approximately 40% of cases (6/15 and 4/9 respectively). There was no mention of incontinence.

An uncontrolled study using topical 1% isosorbide dinitrate applied five times a day in 34 patients produced similar results with a healing rate of 88% (30/34 cases) at 12 weeks.42 There was a 7% (2/30 cases) relapse rate at 10 weeks and no further relapse at a mean follow up of 11 months. Six of the 34 patients studied underwent ambulant anal manometry. This revealed that during sleep the anal pressure falls to 39% of ambulatory values. Nitrate ointment therefore only needs to be applied during the day.

Chemical sphincterotomy—botulinum toxin
Botulinum toxin, a neurotoxin released from Clostridium botulinum, prevents the release of acetylcholine from presynaptic axon terminals.
Its action is short lived and full recovery of the synapse is expected within 12 weeks. It is used to treat skeletal muscle disorders including blepharospasm and spasticity associated with cerebral palsy. It is also being evaluated in smooth muscle disorders including achalasia and anismus. Its use in chronic anal fissure was reported in 1993 (table 1). By causing temporary synaptic blockade, botulinum toxin has been shown to relax the internal anal sphincter when injected into it or into the external anal sphincter. By contrast, botulinum toxin injected into the internal anal sphincter has no effect on the external anal sphincter. As the external anal sphincter is not involved in the pathogenesis of anal fissures and may be voluntarily contracted to maintain continence, it makes theoretical sense to avoid paralysing the external anal sphincter if possible. There is evidence that at least 15 units of botulinum toxin A must be injected in order to produce a significant decrease in the MRAP.

A prospective, randomised, double blind, placebo controlled trial in 30 patients with chronic anal fissures revealed a 73% (11/15 cases) healing rate at two months using botulinum toxin A (20 units injected as two 10 unit aliquots into the internal anal sphincter on either side of the fissure) compared with a 13% (2/15 cases) healing rate when saline was injected. The remaining 27% in the treatment group were healed two months later after a further injection of 25 units of botulinum. However, three of 10 patients in the control group who crossed over to botulinum injection at two months dropped out of the study and were treated surgically (giving a 70% successful healing rate in this subgroup). Healing correlated with a reduction in pain and MRAP. There were no relapses at 16 months. One case of temporary flatus incontinence was reported out of 25 patients who received botulinum toxin (that is 4%).

Similar results have also been reported in an uncontrolled study (n=100) after the injection of botulinum toxin into the external anal sphincter (two aliquots each of 2.5 or 5 units—depending on sphincter strength— injected into either side of the fissure). In this study there was no rescue treatment given for those fissures failing to heal. The healing rate was 79% at six months (excluding eight patients who had relapsed within this time), with seven cases of temporary flatus incontinence lasting less than two weeks and two cases of temporary faecal incontinence lasting less than one week. In a subsequent study, 20 patients with recurring chronic anal fissures after initial successful treatment with 5 units of botulinum toxin were given a second dose (5 units), resulting in a 70% (14/20) healing rate at three months. No side effects were observed. This study also investigated the use of a second dose of botulinum toxin (10 units) in 30 patients with chronic anal fissures who had failed to heal after initial treatment with 5 units. The healing rate in this group was 63.3% (19/30) at three months, with transient faecal incontinence observed in 6.7% (2/30) patients.

A smaller study demonstrated a 60% (3/5 cases) healing rate in five patients with chronic anal fissures after injection of the internal anal sphincter with a total of 0.125 ng or 0.25 ng or 1 ng of botulinum toxin A into one or two sites.

Chemical sphincterotomy—calcium antagonists

Calcium channel blockers reduce the contractility of cardiac and smooth muscle myocytes by inhibiting the cellular influx of calcium ions. Consequently, drugs such as nifedipine and diltiazem have been used in the treatment of oesophageal dysmotility with varying degrees of success. Serendipitously, oral diltiazem 80 mg twice daily was noticed to produce immediate relieve of proctalgia fugax in a 44 year old woman being treated for Raynaud’s disease. The proctalgia immediately recurred when the diltiazem was discontinued during warmer weather. Diltiazem 60 mg orally and 2% gel topically have been shown to reduce the MRAP by 21% and 28% respectively in healthy volunteers. Whereas oral diltiazem caused postural dizziness in 20% of cases, topical diltiazem caused no side effects.

A large prospective, randomised, double blind, controlled multicentre trial in 283 patients compared 0.2% nifedipine gel twice daily for three weeks with 1% lidocaine + 1% hydrocortisone acetate gel twice daily for three weeks in the treatment of acute anal fissures. Both groups of patients also used anal dilators. After four weeks, 98% of the nifedipine group were healed compared with 61% of the control group. By six weeks, 74% of the control group were healed; 2% (3/141) of the nifedipine group and 26% (37/142) of the control group subsequently underwent surgical sphincterotomy. No systemic side effects were noted in the nifedipine group. The use of topical nifedipine was noted to reduce MRAP by 30% and maximum squeeze pressure by 16.8%.

An uncontrolled study in 15 patients with chronic anal fissures investigated the use of oral nifedipine 20 mg twice daily. After eight weeks, healing was complete in 60% (9/15) and a further 20% (3/15) were asymptomatic and declined further treatment. One patient withdrew from the study within 24 hours of entering for reasons apparently not related to the treatment. Of the two patients with treatment failure remaining in the study, one was successfully treated with glyceryl trinitrate paste and one underwent surgical sphincterotomy. There was one recurrence in the first month which responded to topical glyceryl trinitrate. Side effects included mild headache (4/15), flushing (10/15), and mild ankle oedema (1/15). All side effects were in the first four weeks of treatment. There were no episodes of incontinence. The first dose of nifedipine caused a 36% reduction in MRAP with no change in maximum squeeze pressure.

Botulinum toxin versus topical glyceryl trinitrate

The choice of conservative treatment for chronic anal fissure was clarified by Brisinda et
when they prospectively randomised 50 patients to receive botulinum toxin (20 units given as two injections to both sides of the internal anal sphincter) or 0.2% glyceryl trinitrate ointment applied twice daily for six weeks. At two months, the healing rate was significantly higher in the botulinum toxin group compared to the glyceryl trinitrate group (96% vs 60% respectively). Healing was also significantly quicker in the botulinum toxin group (88% vs 40% respectively at one month). Twenty per cent (5/25) of patients in the glyceryl trinitrate group developed headaches, causing one patient to leave the study and undergo surgical sphincterotomy. There were no adverse side effects in the botulinum toxin group. Apart from the one patient who underwent surgical sphincterotomy after severe headaches while using glyceryl trinitrate, the remaining failures were successfully treated after crossing over to the other treatment.

There were no relapses after an average follow up of 15 months. Botulinum toxin was noted to reduce the MRAP significantly more than glyceryl trinitrate. Furthermore, in the glyceryl trinitrate group, MRAP was reduced in the 15 success cases but not in the nine failures. The MRAP in the latter group was however reduced in the successful treatment with botulinum toxin. This emphasises the importance of reducing internal anal sphincter hypertonia during the medical management of chronic anal fissure. Maximal squeeze pressure was not affected by either botulinum toxin or glyceryl trinitrate, explaining the absence of incontinence as a side effect in this study.

Although this study revealed no adverse effects with the use of botulinum toxin in the treatment of chronic anal fissures, experience with its use elsewhere has identified potential side effects including generalised muscle weakness (mild botulism), 55 necrotising fasciitis, 56 possible reduced sensitivity to vecuronium, 57 and the development of antibodies depending on the type of toxin used. 58 However, the most likely adverse effect in the treatment of chronic anal fissure is temporary incontinence, especially for flatus. 44 47

Conclusions

Despite surgery’s effective healing of chronic anal fissures, chemical sphincterotomy has the advantages of avoiding long term complications (notably incontinence) and not requiring hospitalisation. Botulinum toxin injection has the advantage of an excellent healing rate, can be repeated if necessary and abolishes the need for patient compliance. It is however expensive and temporary incontinence has been reported with its use. Topical glyceryl trinitrate is cheap, has a good healing rate, and faecal incontinence has not been reported. Its effectiveness, however, depends on patient compliance which may be poor in view of associated headaches and a local burning sensation. Long term follow up is not available on chemical sphincterotomy and therefore the risk of recurrent anal fissure in the future is unknown.

As topical glyceryl trinitrate is simple to apply, achieves satisfactory healing rates and is cheap, the authors recommend this as the first line treatment for chronic anal fissures as it could be prescribed by the general practitioner in the absence of any acute anal pathology. The majority of patients will therefore receive appropriate treatment without waiting to be seen at a surgical outpatient clinic. Patients unresponsive to topical glyceryl trinitrate could then be referred for outpatient botulinum toxin injection followed, in a small number of cases, by lateral internal sphincterotomy for those cases resistant to chemical sphincterotomy.

McCallion, Gardiner


35 Carapeti EA, Kamm MA, McDonald PJ, et al. Randomised controlled trial shows that glyceryl trinitrate heals anal fissures, higher doses are not more effective, and there is a high recurrence rate. *Gut* 1999;44:727–30.


Progress in the understanding and treatment of chronic anal fissure

K McCallion and K R Gardiner

Postgrad Med J 2001 77: 753-758
doi: 10.1136/pmj.77.914.753

Updated information and services can be found at:
http://pmj.bmj.com/content/77/914/753

These include:

References

This article cites 54 articles, 4 of which you can access for free at:
http://pmj.bmj.com/content/77/914/753#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/